ICG

ICG’s Head of Economic and Investment Research, Nicholas Brooks, recently joined Jack Farley on the Monetary Matters podcast. Drawing on ICG’s proprietary private markets data, Nicholas discusses why corporate fundamentals have remained resilient despite geopolitical shocks, how corporate balance sheets are holding up and why he sees rising government debt as a more significant medium-term risk than private-sector balance sheets. Head to the comments to listen, watch or read a summary. #PrivateMarkets #PrivateCapital #Alternatives #Economics #MacroEconomics Capital at risk. Past performance is not a reliable indicator of future results.

Celebrating our 2026 summer interns this National Intern Day. These talented young people are in their fourth week, working across many teams within our London, Luxembourg and Warsaw offices. With another four weeks to go before they head back to university or look to land a full-time, early careers role, ICG’s summer interns will continue to make positive impacts, forge meaningful connections and discover what a career at a global alternative asset manager can offer. Outside of their day-to-day work within host teams and the training they join as a cohort, our interns are spending a percentage of their time on a charitable giving project. This involves researching and pitching how the charity budgets of our employee-led networks could be best-spent. ICG’s employee networks include: ▪️ Elevate (aims to support colleagues from lower socio-economic backgrounds and/or those who are first-generation professionals) ▪️ Evolve (aims to achieve gender equity in our organisation and industry while ensuring that women feel they can prosper at ICG) ▪️ Family & Carers (aims to provide a forum for parents and carers to connect, share and support each other) ▪️ NextGen (aims to engage early career professionals and aims to encourage them to have a collective voice) ▪️ Thrive (aim to promote and facilitate a culture of health, wellness and inclusion to support all employees to ‘thrive’ at work) ▪️ Together (aims to encourage a culture of respect and equality for everyone regardless of their sexual orientation or gender identity) ▪️ UNIFY (aims to promote an inclusive workspace that acknowledges and respects our diverse cultural heritage) Curious about starting your career at ICG? Check out the link in comments to learn more. #NationalInternDay #LifeAtICG #EarlyCareers #PrivateMarkets #PrivateCapital #Alternatives

Our Life Sciences team supports innovative companies developing treatments for patients with unmet needs. Irene Matucci, VP in Life Sciences, shares a day in her #LifeAtICG below. Learn more about what it’s like to work with us via the link in comments. #LifeSciences #DayInTheLife #PrivateMarkets #PrivateCapital

ICG European Mid-Market is pleased to continue supporting ATOZ Services as the company enters its next phase of growth, following a strategic growth investment from Bregal Sagemount in a transaction that will also see ICG reinvest, subject to regulatory approval and other customary procedures.   Founded in 2018, ATOZ provides fund-linked SPV services, fund administration, and governance, risk and compliance services to alternative investment managers. The new partnership will support the company’s geographic expansion, investment in AI and further development of its fund services platform.   Mark Piasecki, Managing Director at ICG, said: “It has been a privilege to support the ATOZ Services team through a successful period of growth, service line expansion and internationalisation. There is significant future headroom, and ICG is delighted to continue supporting Chafai and the team on its growth journey with Bregal Sagemount.”   Our European Mid-Market team draws on ICG’s capital solutions heritage to provide partnership capital to privately owned companies and financial sponsors across the European mid-market. Learn more via the comments below.   #PrivateCapital #PrivateMarkets #Alternatives #MidMarket #Deal   Capital at Risk.

Private companies performed strongly in 2025 and into early 2026 despite high economic and geopolitical volatility, according to data tracked by the ICG Private Company Database. Read Chief Economist Nicholas Brooks' executive summary or the full 10+ page report, via the links in the comments. #PrivateCompanies #Trends #Economics #PrivateMarkets #PrivateCapital #Alternatives Capital at risk. Past performance is not a reliable indicator of future results.

What sits behind long-term performance in private markets? For ICG, part of the answer is disciplined organic growth: finding the right people and teams, building in areas where we have conviction, and staying focused on where we believe we can deliver for clients over time. In the latest episode of Evercore's Flow of Funds podcast, ICG’s David Bicarregui and Brian Spenner speak with Glenn Schorr about our business model, our growth journey, and the culture underpinning the firm. Head to the comments to watch or listen. #PrivateMarkets #PrivateCapital #Alternatives #LifeAtICG Capital at risk. Past performance is not a reliable indicator of future results.

ICG’s Nicholas Brooks returned to CNBC today, joining Steve Sedgwick and Karen Tso to discuss the outlook for the US economy following the recent appointment of Kevin Warsh as Chair of the Federal Reserve. Watch Squawk Box Europe - linked in the comments - to hear Nick’s views on: • What new Fed chairman Warsh’s recent testimony to the US Congress suggests about his approach to inflation and monetary policy - and the Fed’s likely next moves. • Whether the surge in AI-related investment points to a wider economic bubble. • Why understanding the Fed’s reaction function may matter more than formalised Fed forward guidance. • What the resumed disruption of shipping through the Strait of Hormuz means for energy prices and the global economy - and whether markets are underestimating the risks. Nicholas Brooks is Head of Economic and Investment Research at ICG. Read his latest analysis on recent developments in the Middle East via the comments below. #CNBC #PrivateMarkets #PrivateCapital #Alternatives #Economics #MacroEconomics Capital at risk.

ICG today published its Q1 FY27 trading update for the three months ended 30 June 2026. Fee-earning AUM stood at $88bn, up 3% in the quarter and 10% year-on-year on a constant currency basis. Total AUM was $126bn at 30 June 2026. Other Q1 FY27 highlights included: ● $4.1bn of fundraising in the quarter ● Europe IX stood at €11bn at 30 June 2026 and remains on track to close at €12bn in Q2 FY27 ● Dry powder of $36bn, including $18bn not-yet-earning fees #PrivateMarkets #PrivateCapital #Alternatives Capital at risk. Past performance is not a reliable indicator of future results.

Madeleine Cosgrave, Senior Advisor to ICG Real Estate, has been inducted into Property Week’s Hall of Fame at the 2026 Commercial Property Awards, in partnership with James Andrew International. Selected by a panel of senior industry experts, the award celebrates Madeleine’s outstanding career, leadership and commitment to supporting the next generation of talent in commercial property. Congratulations, Madeleine! Learn more about ICG’s Real Estate strategy via the links in the comments. #PrivateMarkets #PrivateCapital #RealEstate Capital at risk.

An important milestone for ICG Life Sciences portfolio company Draig Therapeutics. Draig has closed an oversubscribed $65m Series B financing, a year after launching from stealth mode with $140m in Series A funding. Led by Deep Track Capital, the Series B round received participation from a host of notable investors, including Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences. The proceeds will support accelerated clinical development of Draig’s pipeline of highly specific AMPA and GABAₐ receptor modulators – including lead programme DT-101, an AMPA receptor potentiator currently in Phase 2 studies for major depressive disorder. ICG Life Sciences provided seed funding alongside SV Health Investors to establish and build out Draig, supporting its transition from academia to a commercially driven, clinical-stage biotech company. Dr Samantha B., Venture Partner at ICG Life Sciences and Board Director at Draig, commented: “Neuropsychiatric disorders remain one of the largest areas of unmet medical need globally, and Draig’s innovative approach to developing highly specific therapies has the potential to transform outcomes for patients and their families. Having supported the company since its earliest days, we are delighted to see this financing round attract such a high-quality investor syndicate, further validating the strength of its scientific approach. We look forward to continuing to partner with the team as they advance DT-101 and their broader pipeline through the next stage of development.” Read the full announcement via the comments. #LifeSciences #Healthcare #BioTech #ClinicalStage #PrivateCapital #PrivateMarkets #Alternatives Capital at risk. Past performance is not a reliable indicator of future results.